SAN DIEGO and TOKYO, Japan, June 2 /PRNewswire/ -- ChemBridge Research Laboratories, LLC (hereinafter "CRL", Headquarters: San Diego, Chairman & CEO: Mr. Eugene Vaisberg) and Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced today the achievement of a discovery milestone in their collaboration targeting an undisclosed G-Protein Coupled Receptor (GPCR). The nomination of this milestone triggers further discovery support by CRL facilitating the optimization of identified lead molecules. CRL will continue to receive additional milestone payments if the program progresses. In April 2002, CRL disclosed a drug discovery collaboration with Eisai targeting GPCR's which was amended in December 2003. Further details and financial terms were not disclosed.
"The continuation of our GPCR program with Eisai marks the beginning of an accelerated effort to move potential candidates through preclinical validation," said Sven H. Wagner, Ph.D., Associate Director of Business Development of CRL. "We look forward to further facilitating Eisai's strong research commitment to find new treatments for human diseases with the expertise of CRL scientists utilizing CRL's innovative discovery chemistry platform."
About Eisai Co., Ltd.:
Eisai Co., Ltd. is a research-based human health care company, which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 7,700 people worldwide. Eisai common stock is listed on the Tokyo Stock Exchange and the Osaka Securities Exchange. For additional information, visit Eisai's web site at http://www.eisai.co.jp/index-e.html.
About ChemBridge Research Laboratories, LLC:
ChemBridge Research Laboratories, LLC (CRL), http://www.chembridgeresearch.com/, a discovery chemistry research company based in San Diego, provides integrated collaborative chemistry solutions for all stages of the drug discovery process. Founded in 2000 as a spin-off of ChemBridge Corporation, CRL has quickly built a world-class research organization with a track record of exceeding goals on all its discovery chemistry collaborations including major multi-year strategic alliances with Pfizer and Merck. CRL provides a competitive edge to its partners through its comprehensive medicinal chemistry platform which encompasses efficient solution/solid phase, high-throughput, and versatile large scale chemistry, supported by strong analytical and computational chemistry, as well as complementary bioassay capabilities. With a core expertise in several important drug target super families and access to ChemBridge's entire enabling chemistry tools portfolio, CRL can successfully tackle the design and synthesis of advanced custom and targeted libraries, and the most challenging hit-to-lead, lead optimization, and collaborative discovery chemistry projects. CRL's list of recent partnerships include contract research collaborations with leading pharmaceutical and biotech companies such as Eisai, Genomics Institute of the Novartis Research Foundation, GlaxoSmithKline, Memorial Sloan-Kettering Cancer Center, Merck KGaA, Tanabe and Tularik.
ChemBridge Research Laboratories, LLC